O	0	1	A
O	2	7	multi
O	7	8	-
O	8	14	center
O	15	24	pragmatic
O	24	25	,
O	26	36	randomized
O	36	37	,
O	38	49	feasibility
O	50	55	trial
O	56	65	comparing
O	66	74	standard
O	75	77	of
O	78	82	care
O	83	92	schedules
O	93	95	of
B-intervention	96	106	filgrastim
O	107	121	administration
O	122	125	for
O	126	133	primary
B-condition	134	141	febrile
I-condition	142	153	neutropenia
O	154	165	prophylaxis
O	166	168	in
O	169	174	early
O	174	175	-
O	175	180	stage
O	181	187	breast
O	188	194	cancer
O	194	195	.

O	196	199	The
O	200	204	most
O	205	214	effective
O	215	223	duration
O	224	226	of
O	227	237	filgrastim
O	238	240	as
O	241	248	primary
O	249	256	febrile
O	257	268	neutropenia
O	269	270	(
O	270	272	FN
O	272	273	)
O	274	285	prophylaxis
O	286	288	in
O	289	294	early
O	295	301	breast
O	302	308	cancer
O	309	310	(
O	310	313	EBC
O	313	314	)
O	315	323	patients
O	324	326	is
O	327	334	unknown
O	334	335	.

O	336	343	Despite
O	344	355	significant
O	356	367	differences
O	368	370	in
O	371	375	cost
O	376	379	and
O	380	388	toxicity
O	388	389	,
O	390	392	no
O	393	404	prospective
O	405	410	trial
O	411	414	has
O	415	419	been
O	420	429	performed
O	430	432	to
O	433	441	optimize
O	442	450	practice
O	450	451	.

O	452	454	We
O	455	463	assessed
O	464	467	the
O	468	479	feasibility
O	480	482	of
O	483	488	using
O	489	490	a
O	491	496	novel
O	497	506	pragmatic
O	507	512	trial
O	513	518	model
O	519	521	to
O	522	529	compare
O	530	533	the
O	534	538	most
O	539	547	commonly
O	548	552	used
O	553	562	schedules
O	563	565	of
O	566	576	filgrastim
O	576	577	.

B-eligibility	578	583	Early
I-eligibility	584	590	breast
I-eligibility	591	597	cancer
I-eligibility	598	606	patients
I-eligibility	607	616	receiving
I-eligibility	617	629	chemotherapy
O	630	634	were
O	635	645	randomized
O	646	648	to
O	649	650	5
O	650	651	,
O	652	653	7
O	653	654	,
O	655	657	or
O	658	660	10
O	661	665	days
O	666	668	of
O	669	679	filgrastim
O	680	682	as
O	683	690	primary
O	691	693	FN
O	694	705	prophylaxis
O	705	706	.

O	707	710	The
O	711	716	trial
O	717	728	methodology
O	729	739	integrated
O	740	745	broad
O	746	757	eligibility
O	758	766	criteria
O	766	767	,
O	768	774	simply
O	775	782	defined
O	783	792	endpoints
O	792	793	,
O	794	796	an
O	797	807	integrated
O	808	815	consent
O	816	821	model
O	822	835	incorporating
O	836	840	oral
O	841	848	consent
O	848	849	,
O	850	853	and
O	854	857	web
O	857	858	-
O	858	863	based
O	864	877	randomization
O	878	880	in
O	881	884	the
O	885	891	clinic
O	891	892	.

O	893	904	Feasibility
O	905	908	was
O	909	918	reflected
O	919	926	through
O	927	928	a
O	929	940	combination
O	941	943	of
O	944	951	primary
O	952	961	endpoints
O	962	971	including
B-outcome-Measure	972	979	patient
I-outcome-Measure	980	983	and
I-outcome-Measure	984	993	physician
I-outcome-Measure	994	1004	engagement
O	1005	1006	(
O	1006	1008	if
O	1009	1010	>
O	1011	1013	50
O	1013	1014	%
O	1015	1017	of
O	1018	1029	appropriate
O	1030	1038	patients
O	1039	1049	approached
O	1050	1055	agree
O	1056	1058	to
O	1059	1070	participate
O	1070	1071	,
O	1072	1075	and
O	1076	1078	if
O	1079	1080	>
O	1081	1083	50
O	1083	1084	%
O	1085	1087	of
O	1088	1098	physicians
O	1099	1109	approached
O	1110	1118	patients
O	1119	1122	for
O	1123	1126	the
O	1127	1132	study
O	1132	1133	)
O	1133	1134	.

O	1135	1144	Secondary
O	1145	1154	endpoints
O	1155	1163	included
O	1164	1167	the
B-outcome-Measure	1168	1173	first
I-outcome-Measure	1174	1184	occurrence
I-outcome-Measure	1185	1190	rates
I-outcome-Measure	1191	1193	of
I-outcome-Measure	1194	1196	FN
O	1196	1197	,
B-outcome-Measure	1198	1207	treatment
I-outcome-Measure	1207	1208	-
I-outcome-Measure	1208	1215	related
I-outcome-Measure	1216	1224	hospital
I-outcome-Measure	1225	1234	admission
O	1234	1235	,
O	1236	1238	or
B-outcome-Measure	1239	1251	chemotherapy
I-outcome-Measure	1252	1256	dose
I-outcome-Measure	1257	1267	reductions
I-outcome-Measure	1267	1268	/
I-outcome-Measure	1268	1274	delays
I-outcome-Measure	1274	1275	/
I-outcome-Measure	1275	1290	discontinuation
O	1290	1291	.

O	1292	1296	From
O	1297	1300	May
O	1301	1305	2015
O	1306	1308	to
O	1309	1315	August
O	1316	1320	2016
O	1320	1321	,
B-total-participants	1322	1325	142
O	1325	1326	/
O	1326	1329	149
O	1330	1331	(
O	1331	1333	95
O	1333	1334	.
O	1334	1335	3
O	1335	1336	%
O	1336	1337	)
O	1338	1346	patients
O	1347	1357	approached
O	1358	1364	agreed
O	1365	1367	to
O	1368	1379	participate
O	1380	1383	and
O	1384	1388	were
O	1389	1399	randomized
O	1399	1400	.

B-total-participants	1401	1410	Seventeen
O	1411	1413	of
O	1414	1416	24
O	1417	1418	(
O	1418	1420	70
O	1420	1421	.
O	1421	1422	8
O	1422	1423	%
O	1423	1424	)
O	1425	1432	medical
O	1433	1444	oncologists
O	1445	1455	approached
O	1456	1459	and
O	1460	1470	randomized
O	1471	1479	patients
O	1479	1480	.

O	1481	1484	The
B-total-participants	1485	1488	142
O	1489	1497	patients
O	1498	1506	received
O	1507	1508	a
O	1509	1514	total
O	1515	1517	of
O	1518	1521	495
O	1522	1528	cycles
O	1529	1531	of
O	1532	1544	chemotherapy
O	1544	1545	.

B-outcome	1546	1555	Aggregate
I-outcome	1556	1566	incidences
I-outcome	1567	1569	of
I-outcome	1570	1571	a
I-outcome	1572	1577	first
I-outcome	1578	1583	event
I-outcome	1584	1586	by
I-outcome	1587	1594	patient
O	1595	1599	were
B-outcome	1600	1602	FN
O	1603	1604	(
B-iv-bin-abs	1604	1605	8
O	1605	1606	/
B-total-participants	1606	1609	142
O	1609	1610	,
B-iv-bin-percent	1611	1612	5
I-iv-bin-percent	1612	1613	.
I-iv-bin-percent	1613	1614	6
I-iv-bin-percent	1614	1615	%
O	1615	1616	)
O	1616	1617	,
B-outcome	1618	1627	treatment
I-outcome	1627	1628	-
I-outcome	1628	1635	related
I-outcome	1636	1651	hospitalization
O	1652	1653	(
B-iv-bin-abs	1653	1654	6
O	1654	1655	/
B-total-participants	1655	1658	142
O	1658	1659	,
B-iv-bin-percent	1660	1661	4
I-iv-bin-percent	1661	1662	.
I-iv-bin-percent	1662	1663	2
I-iv-bin-percent	1663	1664	%
O	1664	1665	)
O	1665	1666	,
B-outcome	1667	1679	chemotherapy
I-outcome	1680	1695	discontinuation
O	1696	1697	(
B-iv-bin-abs	1697	1698	7
O	1698	1699	/
B-total-participants	1699	1702	142
O	1702	1703	,
B-iv-bin-percent	1704	1705	4
I-iv-bin-percent	1705	1706	.
I-iv-bin-percent	1706	1707	9
I-iv-bin-percent	1707	1708	%
O	1708	1709	)
O	1709	1710	,
B-outcome	1711	1723	chemotherapy
I-outcome	1724	1730	delays
O	1731	1732	(
B-iv-bin-abs	1732	1733	5
O	1733	1734	/
B-total-participants	1734	1737	142
O	1737	1738	,
B-iv-bin-percent	1739	1740	3
I-iv-bin-percent	1740	1741	.
I-iv-bin-percent	1741	1742	5
I-iv-bin-percent	1742	1743	%
O	1743	1744	)
O	1744	1745	,
O	1746	1749	and
B-outcome	1750	1762	chemotherapy
I-outcome	1763	1767	dose
I-outcome	1768	1777	reduction
O	1778	1779	(
B-iv-bin-abs	1779	1781	18
O	1781	1782	/
B-total-participants	1782	1785	142
O	1785	1786	,
B-iv-bin-percent	1787	1789	12
I-iv-bin-percent	1789	1790	.
I-iv-bin-percent	1790	1791	7
I-iv-bin-percent	1791	1792	%
O	1792	1793	)
O	1793	1794	.

O	1795	1802	Overall
O	1802	1803	,
O	1804	1806	31
O	1806	1807	.
O	1807	1808	7
O	1808	1809	%
O	1810	1811	(
O	1811	1813	45
O	1813	1814	/
O	1814	1817	142
O	1817	1818	)
O	1819	1821	of
O	1822	1830	patients
O	1831	1834	and
O	1835	1836	9
O	1836	1837	.
O	1837	1838	0
O	1838	1839	%
O	1840	1841	(
O	1841	1843	45
O	1843	1844	/
O	1844	1847	495
O	1847	1848	)
O	1849	1851	of
O	1852	1864	chemotherapy
O	1865	1871	cycles
O	1872	1876	were
O	1877	1887	associated
O	1888	1892	with
O	1893	1896	one
O	1897	1899	of
O	1900	1905	these
O	1906	1911	first
O	1912	1918	events
O	1918	1919	.

O	1920	1924	This
O	1925	1930	study
O	1931	1934	met
O	1935	1938	its
O	1939	1950	feasibility
O	1951	1960	endpoints
O	1960	1961	.

O	1962	1966	This
O	1967	1972	novel
O	1973	1982	pragmatic
O	1983	1988	trial
O	1989	1997	approach
O	1998	2004	offers
O	2005	2006	a
O	2007	2012	means
O	2013	2015	of
O	2016	2025	comparing
O	2026	2034	standard
O	2035	2037	of
O	2038	2042	care
O	2043	2053	treatments
O	2054	2056	in
O	2057	2058	a
O	2059	2068	practical
O	2069	2072	and
O	2073	2077	cost
O	2077	2078	-
O	2078	2087	effective
O	2088	2094	manner
O	2094	2095	.

O	2096	2099	The
O	2100	2105	trial
O	2106	2110	will
O	2111	2114	now
O	2115	2117	be
O	2118	2126	expanded
O	2127	2129	to
O	2130	2137	compare
O	2138	2143	rates
O	2144	2146	of
O	2147	2149	FN
O	2150	2157	between
O	2158	2161	the
O	2162	2167	three
O	2168	2178	filgrastim
O	2179	2188	schedules
O	2188	2189	.

O	2190	2204	ClinicalTrials
O	2204	2205	.
O	2205	2208	gov
O	2208	2209	:
O	2210	2221	NCT02428114
O	2221	2222	.
